Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	1.100 €	+0.92%	36,000
11/06/26	1.090 €	-0.46%	25,000
10/06/26	1.095 €	0.00%	0
09/06/26	1.095 €	0.00%	11,000
08/06/26	1.095 €	-0.45%	21,000

Real-time Borsa Italiana

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Borsa Italiana Other stock markets 18:45:00 12/06/2026 +03			5-day change	1st Jan Change
1.100 ^EUR	+0.92%		0.00%	-25.17%

06-04	Equities trend higher; banks lead gains on the MIB	AN
05-22	European markets rebound; STM and Stellantis lead gains	AN

Market Cap	9.29M 10.7M 8.56M 8.02M 14.99M 1.02B 15.3M 102M 39.54M 494M 40.17M 39.31M 1.72B	P/E Ratio 2024	30.8x	P/E Ratio 2025	17x
Enterprise Value	9.58M 11.04M 8.83M 8.28M 15.46M 1.06B 15.79M 105M 40.79M 510M 41.45M 40.56M 1.77B	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	18.98%	Yield 2024 *	-	Yield 2025	-

06-04	Equities trend higher; banks lead gains on the MIB	AN
05-22	European markets rebound; STM and Stellantis lead gains	AN
05-21	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
05-21	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
05-21	European markets set for lower open; focus on manufacturing PMIs	AN
04-20	Brent rebounds; futures signal risk-off sentiment	AN
04-17	Greenlight on Hormuz sparks global equity rally	AN
04-13	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Laboratorio Farmaceutico Erfo posts triple-digit profit growth in 2025	AN
03-06	IG Futures Point to Higher European Markets	AN
03-05	US-Iran Conflict Fuels Commodity Rally; Mib Slides	AN
03-05	Active Markets; Traders Unconvinced by Nexi	AN
02-23	Europe Expected to Open Lower Amid US Tariff Uncertainty	AN

04-09	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
21/10/25	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
29/08/25	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
04/06/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
19/05/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Stock

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation: Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases: Laboratorio Farmaceutico Erfo S.p.A.

News in other languages: Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-04	Borse rialziste; bene i bancari sul MIB
05-22	Tornano gli acquisti in Europa; su STM e Stellantis
05-21	Laboratorio Farmaceutico Erfo chiude trimestre stabile su base annua
05-21	Laboratorio Farmaceutico Erfo S p A : 2026 05 21 ERFO - CS Dati gestionali Q1 2026 ITA-ENG
05-21	Europee attese giù; focus su PMI manifatturiero

1 day	+0.92%
Current month	+0.92%
1 month	-2.22%
3 months	-5.17%
6 months	-26.42%
Current year	-25.17%

1 week	1.07	1.11
1 month	1.06	1.18
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	55	01/01/2013
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	55	01/01/2013
Flavio Corpina BRD	Director/Board Member	47	01/01/2017
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-16	Alessandro Cutè	Sell	Chief Executive Officer	322,000	3.5778%
12-16	Alessandro Cutè	Sell	Chief Executive Officer	968,000	10.7556%
29/06/22	Alessandro Cutè	Others	Chief Executive Officer	300,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	+0.92%	0.00%	-8.71%	-6.78%	10.7M
ELI LILLY AND COMPANY	-1.23%	+1.50%	+41.43%	+157.90%	1,035B
JOHNSON & JOHNSON	+0.75%	+3.12%	+53.22%	+50.11%	574B
ABBVIE INC.	+0.07%	-0.94%	+16.99%	+63.44%	397B
ROCHE HOLDING AG	+0.58%	+0.77%	+21.19%	+15.95%	324B
ASTRAZENECA PLC	-0.85%	-2.86%	+22.05%	+13.80%	281B
NOVARTIS AG	+0.44%	+3.48%	+24.48%	+34.39%	278B
NOVO NORDISK A/S	+1.66%	+5.61%	-44.67%	-47.49%	193B
AMGEN INC.	+0.12%	+1.27%	+19.08%	+62.87%	191B
GILEAD SCIENCES, INC.	-0.97%	-3.34%	+11.42%	+60.35%	156B
Average	+0.17%	+1.07%	+15.65%	+40.45%	342.99B
Weighted average by Cap.	-0.14%	+2.39%	+28.24%	+72.39%

	2024	2025
Net sales	6.03M 6.95M 5.56M 5.21M 9.73M 666M 9.94M 66.33M 25.68M 321M 26.1M 25.53M 1.12B	9.73M 11.21M 8.97M 8.41M 15.7M 1.07B 16.03M 107M 41.43M 518M 42.1M 41.19M 1.8B
Net income	353K 407K 325K 305K 569K 38.93M 581K 3.88M 1.5M 18.77M 1.53M 1.49M 65.25M	737K 849K 679K 637K 1.19M 81.32M 1.21M 8.1M 3.14M 39.2M 3.19M 3.12M 136M
Net Debt	5.77K 6.65K 5.32K 4.98K 9.31K 636K 9.5K 63.41K 24.55K 307K 24.95K 24.41K 1.07M	295K 340K 272K 255K 477K 32.6M 487K 3.25M 1.26M 15.71M 1.28M 1.25M 54.63M